Home >About Us>Timeline

Timeline

May 2017

2016 Awarded for the DNDi’s Project of the Year by DNDi

Jul.2014 Awarded Ministry of Science, ICT, and Future Planning (MSIP)’s 100 Best National R&D project (Q203)

Nov.2013 Awarded for Outstanding Biosafety Management by the Ministry of Health and Welfare

Sep.2013 Ranked top in Lab Biosafety Know-How by Korea’s Ministry of Science, ICT, and Future Planning (MSIP)

Dec.2012 Dr. Jiyoung Kang, Head of Safety Management (former), recognized as a person of scientific merit by Gyeonggi Province

2011 Awarded for the Partnership of the Year by DNDi

Dec.2010 IPK’s facility is recognized as Outstanding Architecture and Design Silver Award by Gyeonggi Province

2010 Awarded for the Partnership of the Year by DNDi

Nov.2009 Ranked top in Lab Safety by Korea’s Ministry of Education and Science Technology (MEST)

May.2008 First Bio Safety Level 3 facility certified by the Korean Government (Certification issued by KCDC)

Oct.2016 Licensed out a hepatitis C virus drug candidate (Thiophene Urea (TU) compound series) to J2H Biotech

Sep.2016 Memorandum of Understanding (MoU) with Gyeonggi Provincial Government & 5 Gyeonggi based organizations for the [IPK-Pharma-Biotech Drug Discovery Joint Research Project]

Aug.2016 Participated in National Convergent Research of Emerging Virus Infection (CEVI) Program (Development of Anti-Coronavirus small molecules

Feb.2016 Qurient went public on Korea Securities Dealers Automated Quotation (KOSDAQ)

Dec.2015 Q203, a first in class (in Korea) tuberculosis drug candidate, designated as an Orphan Drug (development fast track) by US FDA

Oct.2015 Optimized Lead declared for a first-in-class hepatitis C virus drug candidate

Aug.2015 Master research agreement with DNDi for research collaboration on Leishmania and T. Cruzi

Jul.2015 Q203, a first in class (in Korea) tuberculosis drug candidate, approved for FDA clinical trial phase I

Dec.2014 Participated in KRICT Convergence cluster (anti-bacterial, antiviral, and diagnosis divisions)

May.2014 Designated as University of Science Technology (UST) member campus

Apr.2014 Signed a grant agreement with KDDF for the development of first-in-class hepatitis C virus drug candidate

Dec.2013 Licensed out an anti-inflammatory compound to Qurient Co. Ltd. for drug development

Aug.2013 Discovered Q203, a first in class (in Korea) tuberculosis drug candidate that is highly effective against both multi-drug-resistant (MDR) and extensively drug-resistant Mycobacterium tuberculosis. (Results published in Nature Medicine)

Aug.2013 Master Agreement with DNDi: collaboration to identify and develop safe, effective and affordable new treatments for patients suffering from neglected diseases including Leishmaniasis and Chagas disease

Jun.2013 Discovered a Lead compound, for a first-in-class hepatitis C virus drug candidate

Jan.2012 Selected as a partner in ORCHID alliance, a global project to fight tuberculosis

Mar.2010 Licensed tuberculosis compound I series (Q203) to Qurient Co. Ltd. for drug development

Feb.2010 Licensed tuberculosis compound A series to Qurient Co. Ltd. for drug development

May.2009 New collaboration between GSTEP, INSERM and IPK

Jul.2008 Established Qurient Co. Ltd., an entity for drug development of identified compounds provided by IPK and other research facilities

Sep.2007 First screening agreement with DNDi: Technical Agreement for HTS assay for Leishmania

May.2017 Appointed Dr. Wang-Shick Ryu as Chief Executive Officer of IPK

Dec.2014 10 year anniversary celebration!

May.2014 Appointed Dr. Hakim Djaballah as Chief Executive Officer of IPK

Apr.2009 Relocated to Pangyo Techno Valley campus

Jul.2005 Gyeonggi Province and IPK agree to relocate to Pangyo Techno Valley and be a flagship campus for the new city

Apr.2004 IPK established on Korea Institute of Science and Technology (KIST) campus in Seoul

Mar.2004 Appointed Dr. Ulf Nehrbass as Chief Executive Officer of IPK

Dec.2003 With the support of Korea’s Ministry of Science & Technology (Current: Ministry of Science and ICT), Institut Pasteur and Korea Institute of Science and Technology (KIST) agreed to establish IPK